



डॉ. मनोहर अगनानी, भा.प्र.से.
अपर सचिव

DR. MANOHAR AGNANI, IAS
Additional Secretary



भारत सरकार
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
निर्माण भवन, नई दिल्ली - 110011

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
NIRMAN BHAVAN, NEW DELHI - 110011

D.O. No: T-13020/03/2021-Imm

Date: 17 May, 2021

Dear Sir,

As you may be aware that there is a mechanism to report, investigate, analyse and assess the Adverse Events Following Immunization (AEFI) in the country.

In the light of concerns raised regarding post vaccination embolic and thrombotic events particularly with AstraZeneca-Oxford vaccine [Covishield in India], an in-depth analysis to identify the thromboembolic events (such as Cerebral Venous Sinus Thrombosis, Deep Vein Thrombosis and Pulmonary Embolism) in association with thrombocytopenia (Thrombosis with Thrombocytopenia Syndrome- TTS) following use of COVISHIELD & COVAXIN was conducted.

As per the in-depth analysis of AEFI cases by National AEFI Committee for TTS following COVID-19 vaccination (till 03 April 2021), there is a very miniscule but definitive risk of thromboembolic events following the administration of COVISHIELD vaccine. The reporting rate of these events in India is around 0.61/million doses, which is much lower than the 4 cases/million reported by UK's regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses. There were no potential thromboembolic events reported following COVAXIN.

Although, the observed rates have been less than expected rates for such events, MoHFW would continue to monitor the safety of all COVID-19 vaccines and promote reporting of suspected adverse events for investigations and causality assessments. In this regard, National AEFI Committee has prepared 2 advisories viz. 1) **Advisory for healthcare service providers for Diagnosing and treating Thrombosis and Thrombocytopenic Syndrome (TTS) occurring after administration of COVID-19 vaccine** & 2) **Advisory for vaccine beneficiaries to encourage people to encourage reporting of such events to the health system, be**

Contd...

aware of TTS and seek medical help (enclosed as Annexure).

You are kindly requested to share the first advisory on TTS with all concerned public & private health institutions and professional bodies like IMA, etc. to provide guidance for Diagnosing and treating Thrombosis and Thrombocytopenic Syndrome (TTS) occurring after administration of COVID-19 vaccine. The second advisory to be circulated to all healthcare workers and made available at such platforms so as to create awareness amongst vaccine beneficiaries.

with kind regards,

Yours sincerely,

Enclosures: As above

*7
3
17/05/2021*

(Dr. Manohar Agnani)

Additional Chief Secretary/Secretary/Principal Secretary, Health & family Welfare, All States/UTs

Copy to:

1. Mission Director (NHM), All States/UTs
2. Additional Secretary & Mission Director (NHM)